Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

y developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR®, and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking StatementThe statements in this press release regarding the potential approval and timing of approval of REMOXY by the FDA and subsequent product launch by Pfizer, our anticipated net cash consumption, anticipated clinical trials (including timing and results) for POSIDUR, TRANSDUR-Sufentanil, ELADUR, ORADUR-ADHD and our other drug candidates, the potential benefits and uses of our drug candidates and potential collaborations with third parties are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended e
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
2. DURECT Corporation Announces Third Quarter 2008 Financial Results
3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
7. Genaera Corporation Announces Second Quarter Financial Results
8. MannKind Corporation Reports Second Quarter Financial Results
9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
(Date:7/10/2014)... Wash. The lithium-ion batteries that power our laptops ... longer on a single charge with the help of ... porous material to replace the graphite traditionally used in ... than 10 times the energy storage capacity of graphite. ... battery electrode was published today in Nature Communications ...
(Date:7/10/2014)... study by researchers at the University of Illinois ... mechanisms governing the interplay of spin and heat ... of ultrafast spintronic devices for data storage and ... as well as spin-angular momentum. In a typical ... is no spin current," explained David Cahill, a ...
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3University of Illinois study advances limits for ultrafast nano-devices 2A deeper look at interfaces 2
... - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... the fiscal 2009 third quarter and nine-month period ended ... for its fiscal year 2009 now ending on February, ... period ended February 28, 2009 in the range of ...
... regular improvements in information technology, says Slava Rotkin, but ... Take the laptop, for example. Its components, especially its ... while the instrument,s power and capacity increase. But heat ... melt and the laptop hardware to fail. , Indeed, ...
... Approval for SIMPONI , ... Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: ... granted approval of SIMPONI (TM) (golimumab),as a once-monthly, ... active rheumatoid arthritis (RA), active psoriatic arthritis (PsA),and ...
Cached Biology Technology:Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5New 'near-field' radiation therapy promises relief for overheating laptops 2New 'near-field' radiation therapy promises relief for overheating laptops 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8
(Date:7/11/2014)... news release is available in German . ... is a method that uses the refraction of X-rays ... The images produced with this method are often of ... scientists in the team of Prof. Franz Pfeiffer are ... imaging and therapy including X-ray phase-contrast imaging. One ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... state-of-the-art electron microscopy techniques, a team led by researchers ... described the precise arrangement of chemoreceptorsthe receptors that sense ... have found that this specific architecture is the same ... that this is a stable, universal structure that has ...
... EAST LANSING, Mich. - It,s been cultivated for at least ... every continent except Antarctica. Now the humble potato has had ... important vegetable worldwide," said Robin Buell, an MSU associate professor ... released the first draft sequence of the potato genome. "This ...
... chemicals to observe how basic cellular activities differ between healthy ... too slow or too toxic to perform on live cells. ... Faculty of 1000 Biology and leading authority in chemistry and ... chemical reaction to make live cancer cells light up quickly ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4MSU scientist helps map potato genome, hope to improve crop yield 2